Blastomyces dermatitidis, a dimorphic fungus, causes a localized or disseminated pyogranulomatous fungal infection called blastomycosis. Various descriptive studies have shown predominantly pulmonary, skin, bone, and genitourinary involvement (1). The clinical spectrum of blastomycosis is wide, ranging from subclinical infection to critical cases of acute respiratory distress syndrome. Retrospective studies conducted in recent years have shown an increased incidence of blastomycosis in both Canada and the United States (2–5). Blastomycosis is endemic to the St. Lawrence River Valley; a study that focused on the incidence of blastomycosis in the province of Quebec, Canada (6), showed an increasing incidence from 1988 to 2011. Similar trends have been observed in several regions in the United States (7), although the underlying causes are poorly understood. The absence of robust reporting and lack of reportability in many jurisdictions may hamper the ability to know whether cases are increasing more broadly. Some authors suggested a possible relationship with certain climatic factors (3,8). In the wake of the increased incidence of blastomycosis in Quebec, clinicians have observed a possible worsening of the disease severity in patients, with occasional deaths.

This study aimed to assess temporal changes in the severity and mortality of blastomycosis in Quebec and to identify risk factors for blastomycosis-related deaths. In Quebec, all suspected B. dermatitidis isolates are sent for molecular species confirmation at the Quebec Public Health Laboratory (Laboratoire de Santé Publique du Québec; LSPQ; Sainte-Anne-de-Bellevue, QC, Canada), a Containment Level 3 laboratory. In addition, these strains are maintained in a strain biorepository. Therefore, we also aimed to establish a genetic diversity profile of the circulating Blastomyces strains in Quebec and assess whether major genotypes may be associated with increased disease severity or death. The institutional review board of Centre Intégré Universitaire de Santé et de Services Sociaux de l’Estrie—Centre Hospitalier Universitaire de Sherbrooke (CIUSSSE-CHUS) approved this study (project no. MP-31-2017-1597) and waived the need for individual informed consent because the study involved minimal to no risk to participants and this retrospective research could not practically be carried out without the waiver.

Methods
We conducted a retrospective cohort study in 39 acute-care facilities, including community hospitals and academic centers, in Quebec. The study population included all patients with culture-confirmed
B. dermatitidis infection who were treated as inpatients or outpatients. Data on B. dermatitidis cultures were extracted from the database (1988-2017) of the LSPQ, where all B. dermatitidis isolates are confirmed by an in-house detection PCR coupled with confirmatory sequencing of the internal transcribed spacer region and stored in the repository.

Data Collection and Outcomes

Research assistants reviewed hospital records using a standardized questionnaire. The administrative region of residence was determined using postal codes (9). The medical history was delineated to calculate the Charlson Comorbidity Index (10), along with demographic, microbiological, clinical, and therapeutic data (antifungal drug, dose, route of administration, and start and end dates of treatment). Because there is no consensual definition of disseminated disease, we calculated the total number of organs involved, including the lungs. Immunosuppression included HIV infection, corticosteroid use, immunosuppressive therapy for inflammatory disease, chemotherapy, and transplantation. Severe cases were defined as patients with septic shock or acute respiratory distress syndrome or requiring mechanical ventilation, or any combination of those. The primary outcome was 90-day all-cause mortality.

Case Characteristics and Clinical and Radiologic Manifestations

Most patients were male (143/185; 77%), and the median age was 55 (interquartile range [IQR] 44–67) years. The median duration between the onset of the first symptoms and diagnosis was 56 (IQR 25–123) days. Pulmonary infection (n = 149; 81%) was predominant in this cohort, followed by cutaneous (n = 75; 40.5%), osteoarticular (n = 27, 15%), central nervous system (n = 8, 4%), and urinary (n = 11, 6%) involvement. Two or more organs were involved in 35% (64/185) of the patients. The most frequent symptoms when patients initially sought care were cough (n = 84/185; 45.5%), fever (n = 120; 65%) and dyspnea (n = 97; 52%). Fever was documented in 65 (35%) patients and weight loss in 62 (34%) patients. In patients with pulmonary infections, chest radiograph or computed tomography (CT) scan showed the involvement of >2 lobes in 64 (43%) patients. Radiologic manifestations on chest radiograph, chest CT, or both included, among others, nodular infiltrates (53; 36%), focal masses (27; 18%), and miliary patterns (n = 9; 6%). Furthermore, 122 patients (66%) needed hospitalization for a median duration of 15
(IQR 7–29) days. Of these, 37/122 (30%) patients were admitted to the intensive care unit (median duration 4 days, IQR 2–9 days). A severe form of blastomycosis was observed in 30/185 patients (16%), and the 90-day all-cause mortality was 16% (30/185).

**Temporal Changes in Characteristics, Treatment, and Outcomes of Blastomycosis**

To further investigate temporal changes in blastomycosis, we compared the characteristics of case-patients from 1988–1997 (n = 33) with those identified in 1998–2007 (n = 57) and 2008–2017 (n = 95) (Table 1). We observed a significant increase over time in the age of patients with blastomycosis over the study periods (p = 0.02). In addition, we saw increases in the proportion of diabetic patients, immunocompromised patients, and patients with a Charlson Comorbidity Index score ≥3. Among the case-patients diagnosed during the 2008–2017 period, we noted an increasing use of the lipid formulations of amphotericin B over that of amphotericin B deoxycholate. There was no significant change in the distribution of B. dermatitidis genotypes over time: we observed an increase in the proportion of severe cases over the study periods (1988–1997, 1/33 [3%]; 1998–2007, 8/57 [15%]; 2008–2016, 21/95 [22%]; p = 0.03) (Figure), as well as in the 90-day all-cause mortality (1988–1997, 2/33 [6%]; 1998–2007, 11/54 [18%]; 2008–2016, 18/89 [19%]), but the differences between the study periods were not significant (p = 0.15).

**Table 1. Characteristics of patients in study of blastomycosis in Quebec, Canada**

| Characteristic                          | 1988–1997, n = 33 | 1998–2007, n = 57 | 2008–2017, n = 95 | p value |
|----------------------------------------|-------------------|-------------------|-------------------|---------|
| Median age, y (IQR)                    | 47.4 (42.9–61.2)  | 50.0 (40.4–62.8)  | 58.9 (48.6–70.6)  | 0.02‡   |
| Sex                                    |                   |                   |                   |         |
| F                                      | 11 (33)           | 13 (23)           | 18 (19)           |         |
| M                                      | 22 (67)           | 44 (77)           | 77 (81)           | 0.2     |
| No. involved organs                    |                   |                   |                   |         |
| 1                                      | 17 (52)           | 34 (60)           | 70 (74)           |         |
| ≥2                                     | 16 (48)           | 23 (40)           | 25 (26)           | 0.04    |
| Underlying conditions                  |                   |                   |                   |         |
| Chronic obstructive pulmonary disease  | 6 (18)            | 7 (12)            | 21 (22)           | 0.3     |
| Diabetes                               | 1 (3)             | 9 (16)            | 22 (23)           | 0.03    |
| Immunosuppression                      | 2 (6)             | 11 (19)           | 31 (33)           | 0.005   |
| Charlson Comorbidity Index             |                   |                   |                   |         |
| 0                                      | 20 (61)           | 28 (49)           | 33 (35)           |         |
| 1–2                                    | 11 (33)           | 12 (21)           | 30 (32)           |         |
| ≥3                                     | 2 (6)             | 17 (30)           | 32 (34)           | 0.01    |
| First antifungal administered          |                   |                   |                   |         |
| Amphotericin B, lipid formulations     | 0                 | 5 (9)             | 20 (21)           |         |
| Amphotericin B, deoxycholate           | 5 (15)            | 6 (11)            | 6 (6)             |         |
| Azole                                  | 20 (61)           | 33 (58)           | 58 (61)           |         |
| No treatment                           | 8 (24)            | 13 (23)           | 11 (12)           | 0.008‡  |
| Blastomyces genotype group             |                   |                   |                   |         |
| I                                      | 1 (6)             | 1 (2)             | 1 (2)             |         |
| II                                     | 3 (17)            | 11 (24)           | 11 (24)           |         |
| III                                    | 4 (22)            | 13 (29)           | 14 (30)           |         |
| IV                                     | 10 (56)           | 20 (44)           | 20 (44)           | 0.9     |
| Severe illness                         | 1 (3)             | 8 (15)            | 21 (22)           | 0.03    |
| 90-day all-cause mortality             | 2 (6)             | 10 (18)           | 18 (19)           | 0.2     |

*Values are no. (%) except as indicated. IQR, interquartile range.

†By Mood’s equality of medians test.

‡By Fisher exact test.

Risk Factors for Mortality

Several variables were associated with mortality in univariate analysis but were no longer significant after adjusting for confounders. There was no significant association between genotype and mortality. The independent risk factors associated with mortality included age (p = 0.04), immunosuppression (p = 0.005), and the involvement of ≥2 lung lobes on chest radiograph (p = 0.001) (Table 2).
Table 2. Risk factors for 90-day all-cause mortality among patients with blastomycosis, Quebec, Canada*

| Risk factor                          | Survived, n = 155 | Died, n = 30 | Crude odds ratio (95% CI) | p value | Adjusted odds ratio (95% CI) | p value |
|-------------------------------------|-------------------|-------------|---------------------------|---------|-----------------------------|---------|
| Study period                        |                   |             |                           |         |                             |         |
| 1988–1997                           | 31 (94)           | 2 (6)       | 1                         |         |                             |         |
| 1998–2007                           | 47 (82)           | 10 (18)     | 3.3 (0.7–16.1)            | 0.1     | 2.7 (0.5–15.3)              | 0.3     |
| 2008–2017                           | 77 (81)           | 18 (19)     | 3.6 (0.8–16.6)            | 0.1     | 1.2 (0.2–6.5)               | 0.8     |
| Median no. days of symptoms before diagnosis (IQR) | 71 (26–141)       | 37 (18–45)  | 0.99 (0.99–1.00)          | 0.04    | 0.99 (0.99–1.00)            | 0.07    |
| Median age, y (IQR)                 | 54 (44–64)        | 62 (53–71)  | 1.04 (1.01–1.07)          | 0.004   | 1.04 (1.00–1.07)            | 0.04    |
| Sex                                 |                   |             |                           |         |                             |         |
| F                                   | 34 (81)           | 8 (19)      | 0.8 (0.3–1.9)             | 0.6     |                             |         |
| M                                   | 121 (85)          | 22 (15)     |                           |         |                             |         |
| Charlson Comorbidity Index score    |                   |             |                           |         |                             |         |
| 0                                   | 76 (94)           | 5 (6)       |                           |         |                             |         |
| 1–2                                 | 43 (81)           | 10 (19)     | 3.5 (1.1–16.1)            | 0.03    |                             |         |
| ≥3                                  | 36 (71)           | 15 (29)     | 6.3 (2.1–18.8)            | 0.001   |                             |         |
| Underlying condition                |                   |             |                           |         |                             |         |
| Diabetes                            | 23 (72)           | 9 (28)      | 2.5 (1.00–6.04)           | 0.05    |                             |         |
| COPD                                | 27 (79)           | 7 (21)      | 1.4 (0.6–3.7)             | 0.5     |                             |         |
| Immunosuppression                   | 27 (61)           | 17 (39)     | 6.2 (2.7–14.3)            | <0.001  | 4.2 (1.5–11.6)              | 0.005   |
| No. organs involved                 |                   |             |                           |         |                             |         |
| 1–2                                 | 105 (87)          | 16 (13)     | 1.8 (0.8–4.1)             | 0.1     |                             |         |
| >2                                  | 50 (78)           | 14 (22)     |                           |         |                             |         |
| Radiologic manifestations           |                   |             |                           |         |                             |         |
| No. lobes                           |                   |             |                           |         |                             |         |
| 0–2                                 | 112 (93)          | 8 (7)       |                           |         |                             |         |
| >2                                  | 43 (66)           | 22 (34)     | 7.2 (3.0–17.3)            | <0.001  | 5.3 (1.9–14.3)              | 0.001   |
| Miliary presentation                | 6 (67)            | 3 (33)      | 2.8 (0.7–11.7)            | 0.2     |                             |         |
| First antifungal received           |                   |             |                           |         |                             |         |
| Amphotericin, lipid formulations    | 20 (80)           | 5 (20)      | 1                         |         |                             |         |
| Amphotericin B, deoxycholate        | 13 (76)           | 4 (24)      | 1.2 (0.3–5.5)             | 0.08    |                             |         |
| Azole                               | 107 (96)          | 4 (4)       | 0.1 (0.04–0.61)           | 0.008   |                             |         |
| No treatment                        | 15 (47)           | 17 (53)     | 4.5 (1.4–15.1)            | 0.01    |                             |         |

*Values are no. (%) except as indicated. COPD, Chronic obstructive pulmonary disease; IQR, interquartile range.

Genotype
A total of 108 Blastomyces isolates were available for WGS genotyping. Using WGS data, we detected a total of 97,403 high-quality SNPs among all the isolates sequenced. For the purpose of this study, we used SNP genotype calls across all isolates for structure analysis to underline the major genetic groups present in the population and to assess if they could correlate with disease outcome and severity. We identified 4 main genotypes in the population. Genotype IV (n = 50; 46%) was most frequently isolated, followed by genotype III (n = 31; 28%) and II (n = 25; 23%). Genotype I was isolated infrequently in this study (n = 3; 2%); it formed an outlier group representing the cryptic species B. gilchristii. We saw a correlation between administrative regions and genotypes (Table 3); however, we detected no association between genotypes and the proportion of severe cases or all-cause mortality. Sequences from this study have been deposited in the National Center for Biotechnology Information (project no. PRJNA752385).

Discussion
This study demonstrated a gradual modification in the clinical characteristics and underlying conditions associated with B. dermatitidis infection in Quebec, Canada, over the last 3 decades, 1988–2017. We documented an increase in the proportion of severe cases and an increase in the age and proportion of diabetic and immunocompromised patients. The 90-day all-cause mortality rate remained stable at ≈20% for the last 2 decades despite this change in disease severity. Because blastomycosis is often misdiagnosed as bacterial pneumonia initially (11), and given this changing pattern of disease severity, clinicians in blastomycosis-endemic regions must recognize the possibility of Blastomyces infection earlier to avoid delays in both diagnosis and treatment initiation.

The increased proportion of severe cases observed within our cohort may be related to changes in the underlying characteristics of the affected patients. We observed an increase in the proportion of immunocompromised patients. The prevalence of immunosuppressed adults in Quebec is unknown; an estimated 2.7% of US adults self-reported that they were immunosuppressed in 2013 (12), and this number is thought to be increasing because of both greater life expectancy among immunosuppressed adults and new indications for immunosuppressive therapies (13,14). Furthermore, population aging...
and increasing prevalence of chronic disease and multiple underlying conditions within the population of Quebec may explain the increased proportion of severe cases that were observed since 1998 (15). In addition, there was a similar increase in the prevalence of diabetes in Quebec, from 4.7% in 2000–2001 to 7.2% in 2014–2015 (16). Because our definition of severe cases included, among others, the use of mechanical ventilation, the increase in the proportion of severe cases may also be partially explained by changes leading to increasing use of mechanical ventilation over the years (17).

We observed an overall mortality rate of 16.2% in this study cohort, which is higher than the mortality rate observed in recently published large cohorts. A US nationwide study found an overall in-hospital mortality rate of 6.9% (18), and an overall case-fatality rate in a cohort of 671 cases in Minnesota during 1999–2018 was 10% (19). In a systematic review and meta-analysis, the mortality estimate for general clinical cases of blastomycosis was 6.6% overall (20); substantial heterogeneity between the included studies was mainly attributed to inconsistent definitions of mortality. We used 90-day all-cause mortality, a more robust outcome than other studies that used outcomes such as attributable mortality, which might explain the higher mortality rate in our findings compared with previously published results. Despite the increasing proportion of severe cases, we observed that the case-fatality ratio remained stable over the past 20 years. This observation may reflect improvements in severe sepsis management (21) or mechanical ventilation strategies (22), such as extracorporeal membrane oxygenation, for blastomycosis-related acute respiratory distress syndrome (23). Extracorporeal membrane oxygenation use increased substantially since 2002 (24); this treatment has been shown to decrease deaths in adults with severe acute respiratory failure (25). In addition, we documented the gradual replacement of amphotericin B deoxycholate by lipid formulations of amphotericin B. Despite its well-demonstrated effectiveness, amphotericin B deoxycholate is associated with renal toxicity (26). Patients with AIDS who had disseminated histoplasmosis and were treated with liposomal amphotericin B have demonstrated better clinical outcomes compared with patients who were treated with the deoxycholate forms (27). The increasing use of lipid formulations of amphotericin B may have contributed to the improved patient outcomes in this study, although a head-to-head comparison of amphotericin B formulations for *B. dermatitidis* infection has not been performed in clinical trials. Our study was not adequately powered to verify this hypothesis.

We used WGS to characterize the complete genome of our isolates. The high reproducibility and discriminatory power of WGS (28) enabled us to detect a strong association between genotype groups and the region where patients lived, where we assumed they acquired infection. These findings are similar to those of a study in Canada (29) that showed that the populations of both *Blastomyces* species were associated with major freshwater drainage. Other studies have used polymorphic microsatellite markers to genotype *B. dermatitidis* and have suggested potential associations

| Table 3. Characteristics of patients according to Blastomyces genotype groups, Quebec, Canada* |
|-----------------------------------------------|
| Characteristic | Genotype I, n = 3 | Genotype II, n = 25 | Genotype III, n = 31 | Genotype IV, n = 49 | p value |
| Quebec administrative region | | | | | |
| Bas-St-Laurent | 0 | 0 | 0 | 0 (10) | |
| Saguenay-Lac-St-Jean | 0 | 0 | 0 | 1 (2) | |
| Capitale-Nationale | 0 | 0 | 0 | 13 (27) | |
| Mauricie | 0 | 0 | 1 (3) | 5 (10) | |
| Estrie | 1 (33) | 0 | 25 (81) | 4 (8) | |
| Montréal | 1 (33) | 3 (12) | 3 (10) | 3 (6) | |
| Outaouais | 1 (33) | 10 (40) | 0 | 0 | |
| Chaudière-Appalaches | 0 | 0 | 1 (3) | 5 (10) | |
| Laval | 0 | 1 (4) | 0 | 0 | |
| Lanaudière | 0 | 7 (28) | 0 | 0 | |
| Laurentides | 0 | 1 (4) | 0 | 0 | |
| Montérégie | 0 | 3 (12) | 1 (3) | 4 (8) | |
| Centre-du-Québec | 0 | 0 | 0 | 9 (18) | 0.9† |
| Severe case | | | | | |
| No | 3 (100) | 20 (80) | 27 (87) | 43 (86) | |
| Yes | 0 | 5 (20) | 4 (13) | 7 (14) | 0.8† |
| 90-day all-cause mortality | | | | | |
| No | 3 (100) | 19 (76) | 26 (84) | 41 (82) | |
| Yes | 0 | 6 (24) | 5 (16) | 9 (18) | 0.9† |

*Values are no. (%) except as indicated.
†By Fisher exact test.
between the clinical phenotype and genetic groups of *B. dermatitidis*. Frost et al. found that SNP alleles were substantially different in cases of pulmonary and disseminated disease (30) and identified associations between the group 1 genotype (*B. gilchristii*) and pulmonary infection and between the group 2 genotype and disseminated disease (31). We had a very limited number of *B. gilchristii* infections in our study population and were therefore unable to assess the potential of these 2 groups to cause disseminated diseases within the cohort. We identified 4 main distinct genetic groups that correlate with the geographic origins, but we did not find any association between the genotype and the proportion of severe cases or mortality rate. These results indicate that virulence of *B. dermatitidis* is not correlated with its population genetic structure in Quebec. Nevertheless, we cannot exclude the possibility that virulence may be controlled by specific regions or alleles in the genome. In this case, other approaches could be more suitable such as genome-wide association mapping which reveals SNPs strongly associated with a given virulence trait.

The main limitation of our study is its retrospective nature, which could introduce information bias. We were able to minimize this bias by including on the study team specialized research assistants and infectious diseases fellows who ensured the completeness of data collection. Moreover, this study had limited power to assess the potential factors that could affect mortality rate (e.g., increasing use of lipid formulations of amphotericin B). Furthermore, the cases we analyzed in this study were restricted to patients with a given virulence trait.

The proportion of severe cases of blastomycosis in Quebec has increased over the past 30 years. These changes could be explained in part by the higher proportion of immunosuppressed patients, as well as the older age of infected persons. The study data do not support an increasing virulence of *B. dermatitidis* strains in Quebec. Future studies may help understand whether climate changes or more specific genetic determinants may have played a role in the emergence of more severe *B. dermatitidis* infections, the incidence of which has tripled over time.

This work was supported by the Centre de recherche du Centre hospitalier universitaire de Sherbrooke and The Infectious Disease and Climate Change Fund from Public Health Agency of Canada.

About the Author

Dr Carignan is a professor at the Faculté de Médecine et des Sciences de la Santé de l’Université de Sherbrooke and a clinical research scholar from the Fonds de Recherche en Santé du Québec. His research interests include the epidemiology of emerging infections associated with climate change.

References

1. Bennett JE, Dolin R, Blaser MJ, Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier Health Sciences; 2014.
2. Dworkin MS, Duckro AN, Proia L, Semel JD, Huhn G. The epidemiology of blastomycosis in Illinois and factors associated with death. Clin Infect Dis. 2005;41:e107–11. https://doi.org/10.1086/498152
3. Baumgardner DJ, Knavel EM, Steber D, Swain GR. Geographic distribution of human blastomycosis cases in Milwaukee, Wisconsin, USA: association with urban watersheds. Mycopathologia. 2006;161:275–82. https://doi.org/10.1007/s11046-006-0018-9
4. Morris SK, Brephy J, Richardson SE, Summerbell R, Parkin PC, Jamieson F, et al. Blastomycosis in Ontario, 1994–2003. Emerg Infect Dis. 2006;12:274–9. https://doi.org/10.3201/eid1202.050849
5. Crampton TL, Light RB, Berg GM, Meyers MP, Schroeder GC, Hershfield ES, et al. Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis. 2002;34:1310–6. https://doi.org/10.1086/340409
6. Litvinov IV, St-Germain G, Pelletier R, Paradis M, Sheppard DC. Endemic human blastomycosis in Quebec, Canada, 1988–2011. Epidemiol Infect. 2013;141:1143–7. https://doi.org/10.1017/S0950268812001860
7. Seitz AE, Younes N, Steiner CA, Prevots DR. Incidence and trends of blastomycosis-associated hospitalizations in the United States. PLoS One. 2014;9:e105466. https://doi.org/10.1371/journal.pone.0105466
8. Baumgardner DJ, Paretsky DP, Baeseman ZJ, Schreiber A. Effects of season and weather on blastomycosis in dogs: Northern Wisconsin, USA. Med Mycol. 2011;49:49–55. https://doi.org/10.3109/13693786.2010.488658
9. Elections Quebec. Administrative entities linked to a postal code. 2020 October 20 [cited 2020 Nov 3]. https://www.electionsquebec.qc.ca/english/provincial/electoral-map/administrative-entities-linked-to-a-postal-code.php
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8
11. Lohrenz S, Minion J, Pandey M, Karunakaran K. Blastomycosis in southern Saskatchewan 2000–2015: unique presentations and disease characteristics. Med Mycol. 2018;56:787–95. https://doi.org/10.1093/mmy/myx131
12. Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316:2547–8.
13. Novosad SA, Winthrop KL. Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis. 2014;58:1587–98. https://doi.org/10.1093/cid/ciu104
14. Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2014;58:214–24. https://doi.org/10.1093/cid/cit725

15. Institut National de Santé Publique du Québec. Aging in Québec [cited 2020 Nov 3]. https://www.inspq.qc.ca/le-vieillissement-au-quebec

16. Ins Institut National de Santé Publique du Québec. Diabetes. 2020 [cited 2020 Nov 3]. https://www.inspq.qc.ca/santescope/syntheses/diabete

17. Mehta AB, Syeda SN, Wiener RS, Walkey AJ. Epidemiological trends in invasive mechanical ventilation in the United States: a population-based study. J Crit Care. 2015;30:1217–21. https://doi.org/10.1016/j.jcrc.2015.07.007

18. Rush B, Lother S, Paunovic B, Mooney O, Kumar A. Outcomes with severe blastomycosis and respiratory failure in the United States. Clin Infect Dis. 2021;72:1603–7. https://doi.org/10.1093/cid/ciaa294

19. Ireland M, Klumb C, Smith K, Scheffel J. Blastomycosis in Minnesota, USA, 1999–2018. Emerg Infect Dis. 2020;26:866–75. https://doi.org/10.3201/eid2605.191074

20. Carignan A, Denis M, Abou Chakra CN. Mortality associated with Blastomyces dermatitidis infection: a systematic review of the literature and meta-analysis. Med Mycol. 2020;58:1–10. https://doi.org/10.1093/mmy/myz048

21. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med. 2014;42:625–31. https://doi.org/10.1097/CCM.000000000000026

22. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. https://doi.org/10.1136/bmjopen-2014-004833

23. Bednarzczuk JM, Kethireddy S, White CW, Freed DH, Singal RK, Bell D, et al. Extracorporeal membrane oxygenation for blastomycosis-related acute respiratory distress syndrome: a case series. Can J Anaesth. 2015;62:807–15. https://doi.org/10.1007/s12630-015-0378-z

24. McCarthy FH, McDermott KM, Kini V, Gutsche JT, Wald JW, Xie D, et al. Trends in U.S. extracorporeal membrane oxygenation use and outcomes: 2002–2012. Semin Thorac Cardiovasc Surg. 2015;27:81–8. https://doi.org/10.1053/j.semtcvs.2015.07.005

25. Peek GJ, Mugford M, Thalanany MM, Wilson A, Allen E, Thalanany MM, et al.; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2006;374:1351–63. https://doi.org/10.1016/S0140-6736(06)61069-2

26. Girois SB, Chapuis F, Decullier E, Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2006;25:138–49. https://doi.org/10.1016/s0140-6736(06)60080-0

27. Johnson PC, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al.; US National Institute of Allergy and Infectious Diseases Mycoses Study Group. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105–9. https://doi.org/10.1093/infdis/jis756

28. Araujo R. Towards the genotyping of fungi: methods, benefits and challenges. Curr Fungal Infect Rep. 2014;8:203–10.

29. McTaggart LR, Brown EM, Richardson SE. Phylogeographic analysis of Blastomyces dermatitidis and Blastomyces gilchristii reveals an association with North American freshwater drainage basins. PLoS One. 2016;11:e0159396. https://doi.org/10.1371/journal.pone.0159396

30. Frost HM, Anderson JL, Ivacic L, Sloss BL, Embil J, Meece JK. Development and validation of a novel single nucleotide polymorphism (SNP) panel for genetic analysis of Blastomyces spp. and association analysis. BMC Infect Dis. 2016;16:509. https://doi.org/10.1186/s12879-016-1847-x

31. Meece JK, Anderson JL, Gruszka S, Sloss BL, Sullivan B, Reed KD. Variation in clinical phenotype of human infection among genetic groups of Blastomyces dermatitidis. J Infect Dis. 2013;207:814–22. https://doi.org/10.1093/infdis/jis756

Address for correspondence: Alex Carignan, Department of Microbiology and Infectious Diseases, Université de Sherbrooke, 3001, 12th Ave N, Sherbrooke, QC J1H 5N4, Canada; email: Alex.Carignan@USherbrooke.ca
Changing Patterns of Disease Severity in *Blastomyces dermatitidis* Infection, Quebec, Canada

Appendix

**Appendix Figure.** Population structure analysis of *Blastomyces dermatitidis* fungi based on 97,403 SNPs genotype calls across 108 strains. Each vertical line represents a strain and each color a separate population.